Notably, CBP can acetylate the transcription factor olig1 and regulate its nuclear to cytoplasmic localisation, which is associated with oligodendrocyte differentiation (Dai et al., 2015), and p300 levels have been shown to be altered in a subset of patients with MS (Pedre et al., 2011). The gene discussed is EP300; the disease is myeloid sarcoma.